Kelun's $250M PIPE; Val­ne­va moves chikun­gun­ya vac­cine to Phase 3 for kids

Plus, news about Tre­vi Ther­a­peu­tics:

Kelun Biotech’s $250M stock sale: The Sichuan com­pa­ny up­sized its PIPE from $200 to $250 mil­lion and in­clud­ed in­vestors from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER